Real-world effectiveness of durvalumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin in advanced gallbladder cancer: a study using the TriNetX global network.

Ther Adv Med Oncol · 2025 · PMC12602978 · PMID 41229525

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

6 However, subgroup analysis revealed that only 25% of enrolled patients had GBC, and the survival benefit associated with durvalumab in this subgroup did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.